Phase 1
N=20
A Study of Relative Bioavailability and Food Effect Study of Cobimetinib in Healthy Participants
Healthy Volunteers
Bottom Line
View on ClinicalTrials.gov: NCT01249131 ↗Enrolled (actual)
20
Serious AEs
0.0%
Results posted
Jul 2016
Primary outcome: Primary: Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) — 780; 717; 858 nanograms*hours/milliliter (ng*hr/mL)
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 1
- Interventions
- Cobimetinib (Drug)
- Age
- Adult · 18+ yrs
- Sex
- All
- Sponsor
- Genentech, Inc.
- Primary completion
- Jan 2011
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) |
780; 717; 858 | — |
| PRIMARY Maximum Observed Plasma Concentration (Cmax) |
16.0; 14.9; 17.2 | — |
| PRIMARY Minimum Observed Plasma Concentration (Cmin) |
0.307; 0.36; 0.361 | — |
| PRIMARY Apparent Oral Clearance (CL/F) |
25.6; 25.2; 23.3 | — |
| PRIMARY Apparent Volume of Distribution (V/F) |
2103; 1930; 1900 | — |
Summary
This study will be an open-label, randomized, 3-way, 6-sequence crossover study in healthy participants for determining the relative bioavailability of the tablet formulation to the capsule formulation and the effect of food on the relative bioavailability of the tablet formulation.
Eligibility Criteria
Inclusion Criteria
- Within body mass index range 18.5 to 29.9 kilograms per meter square (kg/m^2)
- In good health, determined by no clinically significant findings from medical history, 12-lead electrocardiogram (ECG) and vital signs
- Clinical laboratory evaluations within the reference range for the test laboratory
- Negative test for selected drugs of abuse at Screening and at each Check-in
- Negative hepatitis panel and anti-hepatitis C virus and negative human immunodeficiency virus (HIV) antibody screens
- Healthy males and females of non-child-bearing potential or who agree to use effective contraception
Exclusion Criteria
- Significant history or clinical manifestation of any significant metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, or psychiatric disorder
- History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance
- History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs except that appendectomy, hernia repair, and cholecystectomy will be allowed
- History or presence of an abnormal ECG
- History of alcoholism or drug addiction prior to study start
- Use of any tobacco-containing or nicotine-containing products prior to study start
- Participation in any other investigational study drug trial in which receipt of an investigational study drug occurred within 28 days or 5 half-lives, whichever is longer, prior to study start
- Use of any prescription medications/products, including proton pump inhibitors, within 14 days prior to study start
- Poor peripheral venous access
- Any acute or chronic condition that would limit the participant's ability to complete and/or participate in this clinical study
- Female participant is pregnant, lactating, or breastfeeding
- Predisposing factors to retinal vein occlusion (RVO)
Data sourced from ClinicalTrials.gov (NCT01249131). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.